Working… Menu
Trial record 46 of 495 for:    LENALIDOMIDE AND every 28 days

Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00434239
Recruitment Status : Unknown
Verified January 2013 by Peter MacCallum Cancer Centre, Australia.
Recruitment status was:  Active, not recruiting
First Posted : February 13, 2007
Last Update Posted : January 10, 2013
Celgene Corporation
Information provided by (Responsible Party):
Peter MacCallum Cancer Centre, Australia

Brief Summary:
This study is mainly assessing the safety of Revlimid in combination with Ancestim (recombinant human stem cell factor) in patients with symptomatic myelodysplasia. Of those two compounds, Revlimid has been shown to be an active drug in myelodysplasia. Clinical responses will also be assessed.

Condition or disease Intervention/treatment Phase
Myelodysplasia Drug: Lenalidomide + Ancestim Early Phase 1

Detailed Description:

Aim: The primary objective is to assess the safety of Revlimid in combination with Ancestim in patients with symptomatic myelodysplasia. The secondary objectives are: Duration of response and assessment of changes in gene expression profile of bone marrow samples from patients undergoing such treatment.

Potential Significance: Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders. Prognosis can be estimated by use of the International Prognostic Scoring System (IPSS) which divides patients into low, intermediate-1, intermediate-2, and high-risk groups with corresponding median survival times of 5.7 years, 3.5 years, 1.2 years, and 0.4 years, respectively. There is currently no standard treatment for MDS and management is often purely symptomatic with transfusion of blood products and antibiotic treatment of infections.

A recent phase II study however has shown significant response rates with Revlimid as a single agent in patients with MDS. The total response rate was 56%. The effects of Revlimid and SCF on hematopoietic progenitors cells were examined in vitro. RhSCF and Revlimid were shown to be synergistic in stimulating the proliferation of hematopoietic progenitor cells and their precursors in vitro, thereby forming the rationale for this study.

Research Plan: This is a single-centre, open label, single-arm, non-comparative study, in which 25 patients will be enrolled. The study will include patients who meet all the inclusion and none of the exclusion criteria, as per the respective protocol section.

The patients will be enrolled sequentially to receive 2 different dose levels of Ancestim with a fixed dose of Revlimid. This will determine the feasibility and tolerability of the combination of Revlimid and Ancestim. Patients will start with an 8 week course of single agent Revlimid as 10mg daily oral treatment day 1-21 in a 28 day cycle. If patients do not achieve a complete remission on single agent Revlimid they will start on Ancestim s.c. injections. Two dose levels of Ancestim (10 and 20 mcg/kg s.c. daily for 7 days) will be evaluated.

Safety: Safety will be assessed by the reporting of adverse events (starting with the first study-related procedure, during treatment, and for a period of 60 days following discontinuation of treatment). The intensity of the adverse events will be assessed using National Cancer Institute common toxicity criteria. All adverse events will be recorded on the case report forms (CRFs). Furthermore, assessments of physical (including neurological / peripheral neurological) examinations, vital signs measurements, and haematology and clinical chemistry tests will be used to monitor safety. Clinically relevant changes in laboratory safety tests, vital signs, and physical examinations will be recorded as adverse events. The adverse event sections of the CRFs will be submitted to a representative of the sponsor at the end of each treatment cycle. Serious adverse events will be reported as they occur, on forms provided by the sponsor.

Efficacy: Response to treatment will be assessed according to the guidelines of the international working group to standardize response criteria for myelodysplastic syndromes. This will be done on bone marrow biopsies (including cytogenetic analyses) and peripheral blood counts. An additional scientific investigation will examine gene-expression profiles of bone-marrow and blood samples at different time points and will try to correlate those with response to treatment. Concomitant in-vitro studies will assess surrogate markers of response.

Statistical Methods: Adverse events, serious adverse events, transfusion requirements, response data and Karnofsky performance status data will be summarized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of the Combination of Lenalidomide (Revlimid®) With Two Different Dose Levels of Short Term Administration of Recombinant Human Stem Cell Factor (rhSCF; Ancestim) for Myelodysplasia.
Study Start Date : February 2007
Actual Primary Completion Date : May 2011
Estimated Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment: Lenalidomide and Ancestim
Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
Drug: Lenalidomide + Ancestim
Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
Other Names:
  • Revlimid
  • rhSCF

Primary Outcome Measures :
  1. Toxicity as defined by NCI-CTCv3.0 [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Response [ Time Frame: 3 years ]
  2. Pharmacodynamics [ Time Frame: defined in protocol ]
  3. Change in Biomarkers [ Time Frame: defined in protocol ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent form.
  2. Age >18 years at the time of signing the informed consent form.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Patients must have a confirmed myelodysplastic syndrome regardless of subgroup according to the WHO classification and their prognostic group. Patients with treatment associated MDS are allowed on this study, however the number is restricted to 10 (50% of patients anticipated to receive combination treatment). Patients with CMML are eligible but restricted in number to up to 3 in total.
  5. The patients must have either:

    1. symptomatic anemia as defined as Hb < 10g/dl OR
    2. transfusion-dependent anaemia as defined as requiring more than 4 units of packed red blood cells over 8 weeks
  6. All previous cancer therapy, including erythropoietin, thalidomide and other experimental therapies must have been discontinued at least 4 weeks prior to treatment in this study.

Exclusion Criteria:

  1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  2. Pregnant or lactating females.
  3. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  4. Use of any other experimental drug or therapy within 28 days of baseline.
  5. Known hypersensitivity to thalidomide.
  6. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  7. Any prior use of Revlimid or SCF.
  8. Concurrent use of other anti-cancer agents or treatments including erythropoietin.
  9. Known positive for HIV or infectious hepatitis, type B or C.
  10. Mast cell diseases (systemic mastocytosis, urticaria pigmentosa or diffuse cutaneous mastocytosis)
  11. History of severe anaphylaxis, asthma, recurrent urticaria, recurrent angiooedema
  12. Known hypersensitivity against to Escherichia coli derived products.
  13. Prior chemotherapy or stem cell transplantation for the treatment of myelodysplasia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00434239

Layout table for location information
Australia, Victoria
Peter MacCallum Cancer Centre
East Melbourne, Victoria, Australia, 3002
Sponsors and Collaborators
Peter MacCallum Cancer Centre, Australia
Celgene Corporation
Layout table for investigator information
Principal Investigator: Miles Prince, Prof. Peter MacCallum Cancer Centre, Australia

Layout table for additonal information
Responsible Party: Peter MacCallum Cancer Centre, Australia Identifier: NCT00434239     History of Changes
Other Study ID Numbers: 06/49
First Posted: February 13, 2007    Key Record Dates
Last Update Posted: January 10, 2013
Last Verified: January 2013
Keywords provided by Peter MacCallum Cancer Centre, Australia:
Pilot trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Myelodysplastic Syndromes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents